Telomir Pharmaceuticals (NASDAQ:TELO) Now Covered by Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Telomir Pharmaceuticals (NASDAQ:TELO - Free Report) in a research report released on Friday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $15.00 price objective on the stock.

Telomir Pharmaceuticals Stock Down 2.1 %

TELO stock traded down $0.09 during midday trading on Friday, hitting $4.15. The company's stock had a trading volume of 121,264 shares, compared to its average volume of 120,291. Telomir Pharmaceuticals has a 52-week low of $3.11 and a 52-week high of $9.44. The firm has a 50-day simple moving average of $4.52 and a 200-day simple moving average of $4.87. The firm has a market capitalization of $123.52 million and a P/E ratio of -7.16.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last released its earnings results on Tuesday, February 4th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.05). On average, sell-side analysts expect that Telomir Pharmaceuticals will post -0.4 earnings per share for the current fiscal year.

Institutional Trading of Telomir Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of Telomir Pharmaceuticals by 73.3% in the 4th quarter. Geode Capital Management LLC now owns 413,677 shares of the company's stock valued at $1,705,000 after acquiring an additional 174,940 shares during the last quarter. Northern Trust Corp increased its stake in Telomir Pharmaceuticals by 211.5% in the fourth quarter. Northern Trust Corp now owns 151,628 shares of the company's stock valued at $625,000 after purchasing an additional 102,948 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Telomir Pharmaceuticals by 1,096.4% during the fourth quarter. JPMorgan Chase & Co. now owns 41,444 shares of the company's stock worth $171,000 after purchasing an additional 37,980 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Telomir Pharmaceuticals by 327.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 46,406 shares of the company's stock worth $191,000 after buying an additional 35,556 shares during the last quarter. Finally, Transce3nd LLC acquired a new position in shares of Telomir Pharmaceuticals in the 4th quarter valued at $119,000.

Remove Ads

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.